Effects of genetics variants of pregnant xenobiotic receptor and on pharmacogenetics and drug metabolism

Abstract

Abstract: The orphan nuclear receptor PXR influence drug-induced effects indirectly by mediating transcription of genes CYP3A4 and MDR1 which play important roles in drug clearance and disposition.Thus, genetic variability in PXR will contribute significantly to drugdrug interactions in clinical practice.This review describes common PXR genetic variants that have been identified to date in the human population and the functional consequence of these variant alleles.In addition, this article also described alternatively spliced variants of PXR which may also contribute to individual variability as well as tissue specific expression.Identification of PXR genetic variants and alternatively spliced mRNAs may ultimately conduce to the evaluation of rationality when drugs given in combination and the predictions of therapeutic effects.

Key words: pregnant xenobiotic receptor, genetics variants, single nucleotide polymorphism, splicing variant, drug metabolism, pharmacogenetics

CLC Number:

R968
R969.1

LIU Yan, YIN You, CHEN Yao, ZHOU Hong-hao. Effects of genetics variants of pregnant xenobiotic receptor and on pharmacogenetics and drug metabolism[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2007, 12(8): 845-849.

References

1 Nishimura M, Naito S, Yokoi T.Tissue-specific mRNA expression profiles of human nuclear receptor subfamilies[J].Drug Metab Pharmacokinet, 2004;19:135-149.
2 Medina-Diaz IM, Arteaga-Illan G, de Leon MB, et al.Pregnane X receptor-dependent induction of the CYP3A4 gene by o, p'-1, 1, 1,-trichloro-2, 2-bis (p-chlorophenyl)ethane[J].Drug Metab Dispos, 2007;35:95-102.
3 Stanley LA, Horsburgh BC, Ross J, et al.PXR and CAR:nuclear receptors which play a pivotal role in drug disposition and chemical toxicity[J].Drug Metab Rev, 2006;38:515-597.
4 Itoh M, Nakajima M, Higashi E, et al.Induction of human CYP2A6 is mediated by the pregnane X receptor with peroxisome proliferator-activated receptor-gamma coactivator 1alpha [J].J Pharmacol Exp Ther, 2006;319:693-702.
5 Al-Dosari MS, Knapp JE, Liu D.Activation of human CYP2C9 promoter and regulation by CAR and PXR in mouse liver[J]. Mol Pharm, 2006;3:322-328.
6 Lemaire G, Mnif W, Pascussi JM, et al.Identification of new human pregnane X receptor ligands among pesticides using a stable reporter cell system[J].Toxicol Sci, 2006;91:501-509.
7 Huwyler J, Wright MB, Gutmann H, et al.Induction of cytochrome P450 3A4 and P-glycoprotein by the isoxazolyl-penicillin antibiotic flucloxacillin[J].Curr Drug Metab, 2006;7:119-126.
8 Eloranta JJ, Meier PJ, Kullak-Ublick GA.Coordinate transcriptional regulation of transport and metabolism[J].Methods Enzymol, 2005;400:511-530.
9 Kurose K, Ikeda S, Koyano S, et al.Identification of regulatory sites in the human PXR (NR1I2)promoter region[J].Mol Cell Biochem, 2006;281:35-43.
10 Gerbal-Chaloin S, Pichard-Garcia L, Fabre JM, et al.Role of CYP3A4 in the regulation of the aryl hydrocarbon receptor by omeprazole sulphide[J].Cell Signal, 2006;18:740-750.
11 Ruhl R, Sczech R, Landes N, et al.Carotenoids and their metabolites are naturally occurring activators of gene expression via the pregnane X receptor[J].Eur J Nutr, 2004;43:336-343.
12 Maher JM, Cheng X, Slitt AL, et al.Induction of the multidrug resistance-associated protein family of transporters by chemical activators of receptor-mediated pathways in mouse liver [J].Drug Metab Dispos, 2005;33:956-962.
13 Cheng X, Maher J, Dieter MZ, et al.Regulation of mouse organic anion-transporting polypeptides (Oatps)in liver by prototypical microsomal enzyme inducers that activate distinct transcription factor pathways[J].Drug Metab Dispos, 2005;33: 1276-1282.
14 Chang TK, Bandiera SM, Chen J.Constitutive androstane receptor and pregnane X receptor gene expression in human liver: interindividual variability and correlation with CYP2B6 mRNA levels[J].Drug Metab Dispos, 2003;31:7-10.
15 Zhang J, Kuehl P, Green ED, et al.The human pregnane X receptor:genomic structure and identification and functional characterization of natural allelic variants[J].Pharmacogenetics, 2001;11:555-572.
16 Koyano S, Kurose K, Ozawa S, et al.Eleven novel single nucleotide polymorphisms in the NR1I2 (PXR) gene, four of which induce non-synonymous amino acid alterations[J].Drug Metab Pharmacokinet, 2002;17:561-565.
17 LimYP, Liu CH, Shyu LJ, et al.Functional characterization of a novel polymorphism of pregnane X receptor, Q158K, in Chinese subjects[J].Pharmacogenet Genomics, 2005;15:337-341.
18 Uno Y, Sakamoto Y, Yoshida K, et al.Characterization of six base pair deletion in the putative HNF1-binding site of human PXR promoter[J].J Hum Genet, 2003;48:594-597.
19 Bertilsson G, Heidrich J, Svensson K, et al.Identification of a human nuclear receptor defines a new signaling pathway for CYP3A induction[J].Proc Natl Acad Sci USA, 1998;95: 12208-12213.
20 Lamba V, Yasuda K, Lamba JK, et al.PXR(NR1I2):splice variants in human tissues, including brain, and identification of neurosteroids and nicotine as PXR activators[J].Toxicol Appl Pharmacol, 2004;199:251-265.
21 Vyhlidal CA, Rogan PK, Leeder JS.Development and refinement of pregnane X receptor (PXR)DNA binding site model using information theory:insights into PXR-mediated gene regulation[J].J Biol Chem, 2004;279:46779-46786.
22 Lamba J, Lamba V, Schuetza E.Genetic Variants of PXR (NR1I2) and CAR (NR1I3) and Their Implications in Drug Metabolism and Pharmacogenetics[J].Curr Drug Metab, 2005; 6:369-383.
23 Mensah-Osman EJ, Thomas DG, Tabb MM, et al.Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines[J].Cancer, 2007; 109:957-965.
24 Hustert E, Zibat A, Presecan, et al.Natural protein variants of pregnane X receptor with altered transactivation activity toward CYP3A4[J].Drug Metab Dispos, 2001;29:1454-1459.

[1]	WANG Shuang, LIU jia, ZHANG Yueli. Associations of POR*28 polymorphisms with tacrolimus stable dose in Chinese kidney transplantation patients [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(9): 991-997.
[2]	ZHANG Yuanjin, HUANG Shengbo, LIU Jie, WANG Xin. Construction and application of innovation gene-edited rats and intestinal 3D organoids models in drug metabolism and pharmacokinetics [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(8): 914-922.
[3]	CHEN Hongzhu, LIU Jianming, ZHOU Fang, JIA Yuanwei, WANG Guangji, ZHANG Jingwei. Effect and mechanism of endogenous metabolism on drug metabolism and disposition [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(5): 580-588.
[4]	XIE Shangchen, LI Wei, LIAO Ping, HE Yijing, MCLEOD Howard L.. Research progress of general anesthesia in the pharmacogenetics [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(2): 217-222.
[5]	ZHANG Yue-li, MING Ying-zi, ZHOU Hong-hao, ZHANG Wei. Tacrolimus pathways:pharmacokinetics,pharmacodynamics and pharmacogenomics [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(9): 1042-1049.
[6]	ZHENG Yi, YIN Ji-ye, ZHOU Hong-hao, LIU Zhao-qian. Advances in relationship of genetic polymorphism with the toxicity caused by platinum-based therapy [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(9): 1051-1056.
[7]	WANG Ping, XU Xiao-jing, BU Feng-xiao, ZHOU Yu, YE An, ZHOU Bo-ting. SNP rs1024750 polymorphism in the EGFR gene significantly influences serum calcium levels in postmenopausal Caucasian women [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(7): 772-779.
[8]	LI Mu-peng, XIONG Yan, CHEN Xiao-ping. Progress in pharmacokinetics, pharmacodynamics and pharmacogenetics of the antiplatelet drug ticagrelor [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(2): 214-222.
[9]	XIE Xiang-rong, WANG Ming, ZHENG Ya-jun, LI Jia-jia, ZHANG Xia, SUN Ling-ling, CHENG Lang, CAO Heng. Association between ABCA1 G2706A polymorphism and lipid-lowering treatment with atorvastatin [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(11): 1259-1262.
[10]	LV Pei-yu, YUAN Hong, ZHOU Hong-hao, OUYANG Dong-sheng. Genetic variation of cytochrome P450 oxidase and personalized medicine [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(11): 1281-1287.
[11]	LI Tai-lin, XIE Hai-tang, XU Biao-bo, PENG Yan, WAN Zi-rui, SUN Hong, ZENG Ying, SHEN Jie, WANG Guo, ZHU Yuan-shan. Genotyping of ABCG2 34G>A polymorphism by allele-specific PCR [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(10): 1111-1115.
[12]	SHI Shu-ya, WANG Lian-sheng. Progress in research of phase Ⅱ metabolisms and their enzymes [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(1): 82-89.
[13]	CHEN Qun, XU Zhe, SUN Hua, XIE Hai-tang. Advances on biological characteristics of PXR and its effect on drug metabolism [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2013, 18(3): 241-246.
[14]	KUANG Ze-min, HUANG Zhi-jun, YANG Guo-ping, YUAN Hong. Apparent pharmacogenetics in antihypertensive therapy [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2013, 18(3): 351-355.
[15]	BAO Mei-hua, ZHANG Yi-wen, CHENG Lin, ZHOU Hong-hao. Pharmacogenetic progress of rosuvastatin in atherosclerosis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2013, 18(2): 234-240.